Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BJSE:920566'
s EV-to-FCF Range Over the Past 10 Years
Min: 3.05 Med: 12.73 Max: 34.04
Current: 17.37
During the past 13 years, the highest EV-to-FCF of Sichuan Zitonggong Pharmaceutical Co was 34.04. The lowest was 3.05. And the median was 12.73.
BJSE:920566's EV-to-FCF is ranked better than 55.5% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.01
vs BJSE:920566: 17.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sichuan Zitonggong Pharmaceutical Co (BJSE:920566) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sichuan Zitonggong Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Sichuan Zitonggong Pharmaceutical Co's share price for today is ¥9.79.
Sichuan Zitonggong Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.590.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sichuan Zitonggong Pharmaceutical Co EV-to-FCF Related Terms
Sichuan Zitonggong Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Zitonggong Pharmaceutical Co EV-to-FCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sichuan Zitonggong Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Zitonggong Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sichuan Zitonggong Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sichuan Zitonggong Pharmaceutical Co's EV-to-FCF falls into.
Sichuan Zitonggong Pharmaceutical Co's current Enterprise Value is ¥1,062.3 Mil.
Sichuan Zitonggong Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥61.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Zitonggong Pharmaceutical Co (BJSE:920566) has a EV-to-FCF of 17.37 as of Aug. 31, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sichuan Zitonggong Pharmaceutical Co and its competitors. This is 36% above median its historical median of 12.73. Over the past decade, Sichuan Zitonggong Pharmaceutical Co's EV-to-FCF has ranged from 3.05 to 34.04. According to the industry distribution chart, Sichuan Zitonggong Pharmaceutical Co ranks #251 out of 564 companies in the Drug Manufacturers industry, placing it in the top 44.5%.
Is Sichuan Zitonggong Pharmaceutical Co's EV-to-FCF too high?
Sichuan Zitonggong Pharmaceutical Co's current EV-to-FCF of 17.37 is 36% above median its 10-year median of 12.73. Over the past 10 years, this metric has ranged from a low of 3.05 to a high of 34.04. The Drug Manufacturers industry median EV-to-FCF is 20.01. Sichuan Zitonggong Pharmaceutical Co's value of 17.37 is 13.2% below this industry median. Based on the distribution chart, Sichuan Zitonggong Pharmaceutical Co ranks #251 out of 564 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sichuan Zitonggong Pharmaceutical Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Zitonggong Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sichuan Zitonggong Pharmaceutical Co ranks #251 out of 564 companies for EV-to-FCF. This puts Sichuan Zitonggong Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 20.01. Sichuan Zitonggong Pharmaceutical Co's value of 17.37 is 13.2% below this benchmark. Historically, Sichuan Zitonggong Pharmaceutical Co's own EV-to-FCF has ranged from 3.05 to 34.04 over the past decade. While the company's 10-year median is 12.73 vs. the industry median of 20.01, Sichuan Zitonggong Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.01, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sichuan Zitonggong Pharmaceutical Co's current EV-to-FCF of 17.37 is 13.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sichuan Zitonggong Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Zitonggong Pharmaceutical Co's current EV-to-FCF is 17.37, which is 36% above median its own 10-year median of 12.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Zitonggong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Zitonggong Pharmaceutical Co (BJSE:920566) is currently considered Fairly Valued. The stock's GF Value™ is ¥10.55, compared to a current price of ¥9.79 — trading 7.2% below its estimated fair value. The current EV-to-FCF is 17.37, which is 36% above median its 10-year median of 12.73 and 13.2% below the Drug Manufacturers industry median of 20.01. Sichuan Zitonggong Pharmaceutical Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sichuan Zitonggong Pharmaceutical Co (BJSE:920566), the current EV-to-FCF is 17.37 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Zitonggong Pharmaceutical Co (BJSE:920566) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Zitonggong Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥9.79 is trading 7.2% below its estimated GF Value™ of ¥10.55.
GuruFocus considers Sichuan Zitonggong Pharmaceutical Co to be Fairly Valued.
Key valuation signals for BJSE:920566:
EV-to-FCF: 17.37 (36% above median its 10-year median of 12.73)
GF Value™: ¥10.55 vs. price of ¥9.79 (7.2% below fair value)
Industry Position: 13.2% below the Drug Manufacturers median (#251 of 564)
No single metric tells the full story. See the BJSE:920566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Zitonggong Pharmaceutical Co Ltd is a high-tech enterprise focusing on the R&D, production, and marketing of tablets, hard capsules, liniments, powders, and ointments. It has developed a number of drug varieties, such as Citicoline Sodium Tablets and Rizatriptan Benzoate Capsules.
83GF Score
Get the complete analysis for BJSE:920566
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920566 has been successfully added to your 
